No Detail Found!

Clostridium difficile versus general gastroenteritis: A critical review of a concept

Author(s)
Azadeh Nasrollah Department of Clinical Pharmacy, Islamic Azad University Pharmaceutical Sciences Branch, Tehran, Iran
Shiva Hashemi Department of Clinical Pharmacy, Islamic Azad University Pharmaceutical Sciences Branch, Tehran, Iran
Parvin Talebloo Department of Clinical Pharmacy, Faculty of Pharmacy, Prescribing Analysis and Auditing Centre, Boali Teaching Hospital, Tehran, Iran
Mehdi Rajabi Department of Clinical Pharmacy, Islamic Azad University Pharmaceutical Sciences Branch, Tehran, Iran
Abstract
Objective: Clostridium difficile is the most important definable cause of healthcarea-cquired diarrhea which is mostly associated with inappropriate use of broad-spectrum antibiotics. Recommended treatments for C. difficile infection (CDI) are metronidazole, oral vancomycin, and fidaxomicin (a new narrow spectrum macrocyclic antibiotic). The aim of this investigation was to review the chosen management of general gastroenteritis against risks associated with inappropriate therapeutic options such as CDI in the largest teaching medical school in Iran. Methods: Two thousand medical records and prescriptions were scrutinized, between March 2012 and July 2013 in Phase 1 and September 2014-January 2015 in Phase 2 for patients complaining of diarrhea, colitis, and gastroenteritis. The therapeutic route was investigated in each individual case bearing in mind the medical and medication history as well as other comorbidities. The selection of antibiotic by many medical practitioners for the treatment of mentioned complaints was inappropriate and random. Results: In most cases, the chosen antibiotic can itself be associated with initiation or worsening of CDI. Although there is no official report on resistance to metronidazole or oral vancomycin at this stage, this unrestricted antibiotic use must be addressed. Conclusions: The needs for antimicrobial stewardship programs to preserve the effectiveness of current available therapies are strongly recommended. This program must focus on the overall reduction of inappropriate antibiotic prescribing and ultimately on enforcing the adherence to the reputable antibacterial guidelines.
Publication Details
Page(s) 149-158
Published Journal: Archives of Pharmacy Practice, Volume: 7, Issue: 4, Year: 2016

Request the full text from PASTIC

Keywords
Colitis, Inpatient, fidaxomicin, Clostridium difficile, Outpatient
References
Navaneethan U,Venkatesh PG,Shen B .2010 .Clostridium difficile infection and inflammatory bowel disease: Understanding the evolving relationship. World J Gastroenterol, 16 : 4892-904.
.2013 .. 2015 Feb, 02 : .
Nerandzic MM,Mullane K,Miller MA,Babakhani F,Donskey CJ .2012 .Reduced acquisition and overgrowth of vancomycin‑resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis, 55(Suppl 2) : S121-6.
Sears P,Crook DW,Louie TJ,Miller MA,Weiss K. .2012 .Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis, 55(Suppl 2) : S116-20.
Louie TJ,Cannon K,Byrne B,Emery J,Ward L,Eyben M .2012 .Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis, 55(Suppl 2) : S132-42.
Daniels T,So TY .2011 .Fidaxomicin for the treatment of Clostridium difficile infection in the pediatric population - Not quite so soon yet. Gastroenterol Res, 4 : 936.
Babakhani F,Bouillaut L,Gomez A,Sears P,Nguyen L,Sonenshein AL .2012 .Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis, 55(Suppl 2) : S1629.
Louie TJ,Miller MA,Mullane KM,Weiss K,Lentnek A,Golan Y .2011 .Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med, 364 : 4223-1.
Hashemi S,Nasrollah A,Rajabi M. .2013 .Irrational antibiotic prescribing: A local issue or global concern?. EXCLI J, 12 : 384-95.
Tillotson G,Tillotson J,Clostridium J .2011 .- A moving target. F1000 Med Rep, 3 : 6.
Figueroa I,Johnson S,Sambol SP,Goldstein EJ,Citron DM,Gerding DN .2012 .Relapse versus reinfection: Recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis, 55(Suppl 2) : S104-9.
Crook DW,Walker AS,Kean Y,Weiss K,Cornely OA,Miller MA .2012 .Fidaxomicin versus vancomycin for Clostridium difficile infection: Meta‑analysis of pivotal randomized controlled trials. Clin Infect Dis, 55(Suppl 2) : S93-103.
Weiss K,Allgren RL,Sellers S .2012 .Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections. Clin Infect Dis, 55(Suppl 2) : S1105.
Mullane KM,Miller MA,Weiss K,Lentnek A,Golan Y,Sears PS .2011 .Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis, 53 : 440-7.
Wilkins TD,Lyerly DM .2003 .Clostridium difficile testing: After 20 years, still challenging. J Clin Microbiol, 41 : 5314.
Gerding DN,Johnson S,Peterson LR,Mulligan ME,Silva J .1995 .Clostridium difficile‑associated diarrhea and colitis. Infect Control Hosp Epidemiol, 16 : 459-77.
Walley T,Milson D. .1990 .Loperamide related toxic megacolon in Clostridium difficile colitis. Postgrad Med J, 66 : 582.
Ananthakrishnan AN,Issa M,Binion DG .2010 .Clostridium difficile and inflammatory bowel disease. Med Clin North Am, 94 : 135-53.
Ambrose N. .1989 .The effects of single doses of antibiotics on fecal flora with a reference to their mode of excretion. J Drug Dev, : 233-41.
Bartlett JG. .2002 .Clinical practice. Antibiotic‑associated diarrhea. N Engl J Med, 346 : 334-9.
Bignardi GE .1998 .Risk factors for Clostridium difficile infection. J Hosp Infect, 40 : 1-15.
Gaynes R,Rimland D,Killum E,Lowery HK,Johnson TM,Killgore G .2004 .Outbreak of Clostridium difficile infection in a long‑term care facility: Association with gatifloxacin use. Clin Infect Dis, 38 : 640-5.
Loo VG,Poirier L,Miller MA,Oughton M,Libman MD,Michaud S .2005 .A predominantly clonal multii‑nstitutional outbreak of Clostridium difficilea‑ssociated diarrhea with high morbidity and mortality. N Engl J Med, 353 : 24429.
Pépin J,Saheb N,Coulombe MA,Alary ME,Corriveau MP,Authier S .2005 .Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficilea‑ssociated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis, 41 : 1254-60.
.2006 .S u n e n s h i n e R H , M c D o n a l d L C . C l o s t r i d i u m difficile‑associated disease: New challenges from an established pathogen. Cleve Clin J Med, 73 : 187-97.
Schutze GE,Willoughby RE .2013 .Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics, 131 : 196-200.
Bartlett JG,Gerding DN. .2008 .Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis, 46(Suppl 1) : S12-8.
0

Citations

0

Downloads

7

Views